循环PD-1阳性调节性T细胞下降预测黑色素瘤免疫检查点阻断治疗更佳结局
BACKGROUND: The role of T regulatory lymphocytes (Tregs) and their immunosuppressive mechanisms in the context of programmed death (PD)-1 blockade is not completely understood.…
要点
- 首个PD-1阻断周期后PD-1+ Treg下降与更好PFS和MSD相关。
- PD-1+ Treg未下降者免疫检查点阻断反应受损且结局更差。
核心结论
- 循环PD-1+ Treg在PD-1阻断治疗开始后快速下降,与黑色素瘤进展和MSD风险降低相关。
- PD-1+ Treg未下降者免疫检查点阻断反应受损且结局更差。
研究设计与样本
- 研究采用流式细胞术分析接受纳武利尤单抗或帕博利珠单抗治疗的黑色素瘤患者循环Treg亚群,并与临床结局进行相关性分析。
临床怎么用
- 监测首个PD-1阻断治疗周期后外周血PD-1+ Treg下降情况可能有助于预测黑色素瘤患者临床结局。
- PD-1+ Treg未下降提示对免疫检查点阻断反应受损,需关注更差结局风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of T regulatory lymphocytes (Tregs) and their immunosuppressive mechanisms in the context of programmed death (PD)-1 blockade is not completely understood. OBJECTIVES: To assess the impact of PD-1-blocking antibody treatment on Treg subpopulations in the blood. METHODS: We studied circulating Treg subpopulations in patients with melanoma under nivolumab or pembrolizumab treatment using flow cytometry and correlated these findings with clinical outcomes. RESULTS: These analyses revealed that the frequency of CD4+ CD25++ CD127- PD-1+ lymphocytes (PD-1+ Tregs) significantly decreased after the first cycle of immunotherapy (23% vs. 8·6%, P = 0·043). Compared with patients who did not show a significant decline of PD-1+ Tregs after the first treatment, those who did had better clinical outcomes with respect to progression-free survival (PFS, P = 0·022) and melanoma-specific death (MSD, P = 0·0038). Multivariate analysis confirmed that a significant decline of PD-1+ Tregs in peripheral blood after the first treatment cycle is a significant predictor of more favourable PFS and MSD (P = 0·04 and 0·017, respectively). Interestingly, the occurrence of immune-related adverse events was also an independent predictor for decreased risk of MSD (P = 0·047; odds ratio 0·064, 95% confidence interval 0·0042-0·97). CONCLUSIONS: We provide preliminary evidence that circulating PD-1+ Tregs rapidly decline after the initiation of treatment with PD-1-blocking antibodies, which is associated with reduced risk of melanoma progression and MSD. Patients showing no decrease of these PD-1+ Tregs in peripheral blood are characterized by an impaired response to immune checkpoint blockade and worse outcome. What's already known about this topic? Programmed death (PD)-1-blocking antibodies are highly effective in melanoma treatment. However, more than half of patients do not benefit from this therapy and to date it is difficult to predict which patients will respond to it. What does this study add? PD-1-blocking antibody therapy rapidly results in a decline of circulating PD-1+ T regulatory cells (Tregs). What is the translational message? Patients showing a decrease of PD-1+ Tregs appear to have better clinical outcome under PD-1 treatment.
引用
- Gambichler T, Schröter U, Höxtermann S, et al. Decline of programmed death-1-positive circulating T regulatory cells predicts more favourable clinical outcome of patients with melanoma under immune checkpoint blockade. Br J Dermatol. 2019. PMID: 31361026. doi:10.1111/bjd.18379
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。